Shares of Johnson & Johnson (JNJ) surged on news of trial data results in relation to the development of a single shot vaccine. However, the company is expecting it’s vaccine to be at least 60% effective which is far lower than industry partners Pfizer (PFE) and Moderna (MRNA) which both now have an effectiveness of 95%.
Johnson & Johnson is several weeks behind competitors Moderna and Pfizer, with the latter announcing Wednesday that it would be filing for emergency use authorization “within days.” However, both Moderna and Pfizer are built on a two-dose model, whereas Johnson & Johnson’s JNJ-78436735 requires a single jab.
However, Johnson & Johnson’s vaccine had snafus of its own, including a pause in the phase 3 trial that launched in late September due to a serious medical event in one of its participants. The company resumed trials in October after an independent safety review. An update said the company had no evidence that the vaccine caused the event.
In a press release posted on Sunday, Johnson & Johnson announced that it would begin testing a two-dose regimen in the ENSEMBLE 2 trial, which would require 30,000 participants and be run parallel to ENSEMBLE.
On Wednesday, the company’s CEO, Alex Gorsky, said during the Washington Economic Club event that until vaccines and therapeutics can be widely distributed, the public would have to rely on public health measures to control the spread of coronavirus, especially as people battle restriction fatigue and head back indoors.
Why Relief Therapeutics (OTC:RLFTF) is a better investment
According to Reason, many people are fearful in getting a vaccine. Upon further research this has been a issue for decades which is simply why therapeutics are a better choice — it removes the barrier of fear for vaccines.
Which is why I bring to your attention, a small company Relief Therapeutics (OTC:RLFTF) which is developing a therapeutic VIP drug called RLF-100 or Aviptadil, data going back decades has shown this drug to be highly effective. The company is developing it for use in severe COVID-19 patients.
Their drug candidate works by using a multimodal mechanism of action that uniquely target the pathways (inhibition of viral replication, deterrence of inflammatory cytokines, prevention of cell death and upregulation of surfactant production) attacked by the SARS-CoV-2 virus (COVID-19), preventing acute lung injury (ALI) which potentially can stop the replication of the virus.
Where to put $100 RIGHT NOW
STOP BUYING STOCKS RIGHT NOW … And start taking a serious look at options, the investment vehicle that is driving stocks like Tesla and Apple to historically unprecedented highs.
Subscribe below to get insight into options trades!